LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

Home・Akciju saraksts・Incyte Corp

Incyte Corp

Slēgts

SektorsVeselības aprūpe

97.14 1.71

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

92.12

Max

97.89

Galvenie mērījumi
By Trading Economics
Ienākumi	4.1M 303M
Pārdošana	-234M 1.3B
P/E Sektora vidējais	13.445 49.701
EPS	1.81
Peļņas marža	23.834
Darbinieki	2,844
EBITDA	-47M 367M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+13.89% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 28. jūl.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-31M 19B
Iepriekšējā atvēršanas cena	95.43
Iepriekšējā slēgšanas cena	97.14

Ziņu noskaņojums

By Acuity

14%

86%

22 / 345 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Bullish Evidence

59.52 / 62.66 Atbalsts un pretestība

Incyte Corp Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 20. maijs 23:31 UTC

Karstas akcijas

Stocks to Watch: Intuit, Applied Digital, Osisko, Banzai

2026. g. 20. maijs 22:52 UTC

Galvenie tirgus virzītāji

Osisko Shares Fall on Planned Convertible Notes Offering

2026. g. 20. maijs 23:47 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 20. maijs 23:47 UTC

Tirgus saruna

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

2026. g. 20. maijs 23:44 UTC

Peļņas

Musk Is In Total Control of SpaceX. The IPO Filing Has Finally Come. -- Barrons.com

2026. g. 20. maijs 23:35 UTC

Tirgus saruna

Gold Edges Lower Amid Slightly Higher U.S. Treasury Yields -- Market Talk

2026. g. 20. maijs 23:30 UTC

Tirgus saruna

Goodman Well-Placed for Earnings Guidance Upgrade -- Market Talk

2026. g. 20. maijs 23:17 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 20. maijs 23:17 UTC

Tirgus saruna

Ryman Healthcare Bull Focusing on Three Areas in FY26 Result -- Market Talk

2026. g. 20. maijs 23:15 UTC

Tirgus saruna

Mainfreight's FY26 Profit Fall May Mask Improving Performance -- Market Talk

2026. g. 20. maijs 23:14 UTC

Peļņas

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 4th Update

2026. g. 20. maijs 23:02 UTC

Tirgus saruna

KMD Brands Faces Two Testing Hurdles -- Market Talk

2026. g. 20. maijs 22:57 UTC

Tirgus saruna

Infratil's Other Assets Deserve Attention, Too -- Market Talk

2026. g. 20. maijs 22:57 UTC

Tirgus saruna

Global Energy Roundup: Market Talk

2026. g. 20. maijs 22:57 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 20. maijs 22:51 UTC

Tirgus saruna

Australia Shares Set to Rise, Continue Whipsaw Week -- Market Talk

2026. g. 20. maijs 22:51 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 20. maijs 22:27 UTC

Tirgus saruna

SpaceX Says It Has Largest Addressable Market in 'Human History' -- Market Talk

2026. g. 20. maijs 22:14 UTC

Tirgus saruna

Moody's Downgrades Mexico's Sovereign Rating -- Market Talk

2026. g. 20. maijs 22:10 UTC

Peļņas

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 3rd Update

2026. g. 20. maijs 22:00 UTC

Peļņas

Intuit Stock Falls on Earnings -- and the Company Plans to Cut 17% of Its Workforce -- Barrons.com

2026. g. 20. maijs 21:38 UTC

Peļņas

Iegādes, apvienošanās, pārņemšana

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 2nd Update

2026. g. 20. maijs 21:27 UTC

Peļņas

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- Update

2026. g. 20. maijs 21:20 UTC

Peļņas

Nvidia CFO: Edge Computing Demand Fell Modestly Due to Higher Memory Prices

2026. g. 20. maijs 21:19 UTC

Peļņas

Nvidia Still Uncertain Whether Shipping to China Will Be Allowed, CFO Says

2026. g. 20. maijs 21:18 UTC

Peļņas

Nvidia on Track to Start Production Shipments of Vera Rubin in Second Half of This Year, CFO Says

2026. g. 20. maijs 21:17 UTC

Peļņas

Nvidia Projects $20B in CPU Revenue This Year, CFO Says

2026. g. 20. maijs 21:17 UTC

Peļņas

Nvidia CFO: Every Major Hyperscaler Engaged in Deploying Vera CPU

2026. g. 20. maijs 21:17 UTC

Peļņas

Nvidia's Vera CPU Opens New $200B Market, CFO Says

2026. g. 20. maijs 21:16 UTC

Peļņas

SpaceX IPO Filing Finally Comes. Mars, Musk, and More Big Things to Watch. -- Barrons.com

Salīdzinājums

Cenas izmaiņa

Incyte Corp Prognoze

Cenas mērķis

By TipRanks

13.89% augšup

Prognoze 12 mēnešiem

Vidējais 108.88 USD 13.89%

Augstākais 135 USD

Zemākais 75 USD

Pamatojoties uz 18 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Incyte Corp — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

18 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 18 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Incyte Corp — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

59.52 / 62.66Atbalsts un pretestība

Bullish events outweigh bearish events.

All events are bearish.

Noskaņojums

By Acuity

22 / 345 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation